最近繼續(xù)回YT開(kāi)世紀(jì)三臺(tái)
結(jié)果流量只夠開(kāi)360P RRRRRR
流量燈一下綠一下紅
還以為是七彩霓虹燈.......
六日再來(lái)繼續(xù)測(cè)試好了....
附帶一提，周二要上臺(tái)報(bào)semiar
感覺(jué)會(huì)被電在臺(tái)上.....
Streptococcuspyogenes (S.pyogenes) has beenrecognized as an important human pathogen since early days of modernmicrobiology. Clinical manifestations, such as pneumonia, septicarthritis, necrotizing fasciitis and genital tract sepsis,attributable to this organism are perhaps the most diverse of otherhuman pathogens. Although major overall reductions of S.pyogenes infectionrates in the modern era, mainly as a result of widespreadimprovements in socioeconomic environment, S.pyogenes stillremains the top ten causes of global morbidity and mortality frominfectious diseases. Based on previous studies, we know that nervoussystem, the immune system and microbial pathogens are closelyinteractive at barrier tissues. Asa result, authors tryto find out how S.pyogenes causesnecrotizing fasciitis and the interactions between the neural andimmune systems.They knockoutstreptolysin S(ΔsagA) experssionandblock the Trpv1function, respectively.Streptolysin S,also called SLS, is onekind of pore-forming toxin and the most common bacterial cytotoxicproteins which released by S.pyogenes. Trpv1,a nonselective cationchannel, provides a sensation of heat and pain on nociceptors. Theresults show that S.pyogenes secretesstreptolysin S (SLS) to directly activate Trpv1 reponsive nociceptorneurons and Trpv1 in turn releases the neuropeptide calcitoningene-related peptide (CGRP)into infected tissues.CGRP can inhibit the recruitment of neutrophils and promote bacterialsurvival. Furthermore,they use botulinum neurotoxin A (BoNT/A) and CGRP antagonism,respectively,to blockneuron-mediated suppression of host defense, thereby preventingand treating S. pyogenes necrotizing infection.They conclude that targeting the peripheral nervous system andblocking neuro-immune communication can bea promisingstrategy to treat highly invasive bacterial infections. Besides, itis advantageof using drugs already approvedby FDA and the treatmentcan be appliedtoother invasivebacterial infections
